Home › Hidradenitis Suppurativa › NCT07287644
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2/3
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year. * Have moderate to severe disease not well controlled by systemic antibiotic treatment. * Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study. Exclusion Criteria: * Have certain infections or other immune conditions. * Recently used medications that could interfere with the study. * Are pregnant or breastfeeding.
About the study
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
What is being tested
- BFB759 (biological)
- Placebo for BFB759 (other)
Sponsor: Bluefin Biomedicine, Inc. · Participants: 210 · Started: Nov 3, 2025
Contact the study team
- Rob Eichelkraut · Phone: +1-214-728-6505
Official record on ClinicalTrials.gov — NCT07287644
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.